Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cynthia Osborne

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2006
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissuesSongdong Meng, Debu Tripathy, Sanjay Shete, et al.
Clinical Breast Cancer|August 30, 2016
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II StudyDenise A Yardley, James Reeves, E Claire Dees, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2004
HER-2 gene amplification can be acquired as breast cancer progressesSongdong Meng, Debasish Tripathy, Sanjay Shete, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2006
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissuesSongdong Meng, Debu Tripathy, Sanjay Shete, et al.
Clinical Breast Cancer|August 30, 2016
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II StudyDenise A Yardley, James Reeves, E Claire Dees, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2004
HER-2 gene amplification can be acquired as breast cancer progressesSongdong Meng, Debasish Tripathy, Sanjay Shete, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Pageof 4